 |
|
Ethnic and Sex Differences in the Prevalence, Treatment, and Control of Dyslipidemia Among Hypertensive Adults in the GENOA Study
John G. O'Meara, PharmD;
Sharon L. R. Kardia, PhD;
Jeffrey J. Armon, PharmD;
C. Andrew Brown, MD;
Eric Boerwinkle, PhD;
Stephen T. Turner, MD
Arch Intern Med. 2004;164:1313-1318.
Background Two ethnically different, community-based samples of hypertensive adults were evaluated to determine the prevalence of dyslipidemia and how often dyslipidemia is drug-treated and controlled by such treatment.
Methods We studied 1286 non-Hispanic black hypertensive subjects from Jackson and 1070 non-Hispanic white hypertensive subjects from Rochester who participated in the Genetic Epidemiology Network of Arteriopathy study. Subjects were categorized according to presence of coronary heart disease and risk factors for coronary heart disease.
Results Prevalence of dyslipidemia was significantly greater among whites than blacks (women, 64.7% vs 49.5%; and men, 78.4% vs 56.7%; P<.001 for both) and among men than women (P .02 in each ethnic group). Among dyslipidemic subjects, treatment with lipid-regulating drugs was significantly more common among whites than blacks (women, 25.4% vs 16.4%, P = .001; and men, 32.6% vs 12.8%; P<.001), and among whites, treatment was significantly more common among men than women (P = .03). With drug treatment, control of dyslipidemia varied from 33.9% (white men) to 51.9% (black men), but the differences among ethnic-sex groups were not statistically significant.
Conclusions Dyslipidemia is highly prevalent in hypertensive adults. Fewer than one third of these adults are drug-treated, and fewer than half of those treated achieve recommended goals. Our findings suggest that an alarming 9 of 10 dyslipidemic hypertensive adults have untreated or undertreated dyslipidemia.
From the Department of Pharmacy Services (Drs O'Meara and Armon) and Division of Nephrology and Hypertension, Department of Internal Medicine (Dr Turner), Mayo Clinic and Foundation, Rochester, Minn; Department of Epidemiology, University of Michigan, Ann Arbor (Dr Kardia); Department of Internal Medicine, University of Mississippi, Jackson (Dr Brown); and Human Genetics Center and Institute of Molecular Medicine, The University of Texas Health Science Center at Houston (Dr Boerwinkle). The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction
Mega et al.
Circulation 2007;115:2822-2828.
ABSTRACT
| FULL TEXT
Recent development of ischaemic heart disease in sex difference
Shu et al.
Postgrad. Med. J. 2007;83:240-243.
ABSTRACT
| FULL TEXT
Quantitative trait loci influencing low density lipoprotein particle size in African Americans
Kullo et al.
J. Lipid Res. 2006;47:1457-1462.
ABSTRACT
| FULL TEXT
Influence of Genomic Loci on Measures of Chronic Kidney Disease in Hypertensive Sibships
Turner et al.
J. Am. Soc. Nephrol. 2006;17:2048-2055.
ABSTRACT
| FULL TEXT
Novel Genomic Loci Influencing Plasma Homocysteine Levels
Kullo et al.
Stroke 2006;37:1703-1709.
ABSTRACT
| FULL TEXT
Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies
Shaw et al.
J Am Coll Cardiol 2006;47:S4-S20.
ABSTRACT
| FULL TEXT
Twenty-Year Trends in Serum Cholesterol, Hypercholesterolemia, and Cholesterol Medication Use: The Minnesota Heart Survey, 1980-1982 to 2000-2002
Arnett et al.
Circulation 2005;112:3884-3891.
ABSTRACT
| FULL TEXT
Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
Wexler et al.
Diabetes Care 2005;28:514-520.
ABSTRACT
| FULL TEXT
|
